Summary. Daunomycin was coupled with the aid of glu
Introduction
So far no therapeutic agents capable of completely eradicating established tumors have been discovered. Although chemotherapeutic agents are highly toxic to tumor cells, they have the disadvantage that they are also toxic to normal tissues. An ideal therapeutic agent should possess high toxicity and specificity for the tumor. In theory, such agents could be prepared by linking cytotoxic drugs to tumor-specific antibodies by chemical methods. However, one of the main difficulties is the production of adequate amounts of specific antitumor antibodies for coupling to drugs.
Several groups of investigators have linked cytotoxic agents to antitumor antibodies in an attempt to use these Reprint requests shouM be addressed to: A. H. Sehon preparations for the destruction of tumor cells. For instance, in an in vitro model system, conjugates consisting of diphtheria toxin coupled to anti-dinitrophenyl (DNP) antibodies were shown to display a potent cytotoxic effect towards tumor cells to which the DNP determinants had previously been attached (Moolten et al., 1972) . Others have linked alkylating agents, either covalently (Linford et al., 1974) or noncovalently (Ghose et al., 1972; Davies and O'Neill, 1973) , directly to antitumor antibodies. Trenimon, nitrogen mustard, adriamytin, and daunomycin have all been conjugated covalently by chemical methods to antitumor antibodies. Such conjugates were shown to retain both pharmacologic and antibody activity, and were able to exert preferential cytotoxicity against tumor cells in vitro (Linford et al., 1974; Hurwitz et al., 1975; Levy et al., 1975) .
As reported previously Lee et al., 1978) , up to 70% of anti-guinea pig fibrin antibodies (AGFA) injected in strain 13 guinea-pigs bearing the 3-methylcholanthrene-induced sarcoma (MC-D) was localized within the fibrin matrix enmeshing this tumor. Hence, in the present study AGFA-daunomycin conjugates were prepared by cross-linking with glutaraldehyde in anticipation that these conjugates would home to the tumor foci and destroy the tumor. Indeed, daunomycin-AGFA conjugates were shown to retain both their drug and their antibody activities. Moreover, multiple intratumoral injections of these conjugates induced in vivo rejection of estabfished MC-D tumors in some guinea-pigs, and the guinea-pigs so cured were resistant to a further injection of a supralethal dose of MC-D cells (Lee et al., 1977) .
Materials and Methods

Guinea-Pigs and Tumor
Inbred SewaU Wright strain-13 guinea pigs weighing 300-400 g were purchased from Weizmann Institute for Science, Rehovot, Is- 
Daunomycin and Goat A GFA
Daunomycin hydrochioride was obtained either as the commercial product, Cerubidine, or as the pure compound, a gift from the manufacturers (Poulenc, Montreal, Quebec). We found no substantial differences in the reactivity of these two products during coupling experiments with AGFA.
Goat AGFA was prepared and purified as described in the preceding paper (Lee et al., 1978) .
Conjugation of Daunomycin with AGFA
The linking of daunomycin to AGFA was achieved according to the method of Hurwitz et al. (1975) , using glutaraldehyde (Baker, Phillipsburg, N.J.) as cross-linking agent. A mixture of daunomycin (0.5 ml, 1 mg/ml) and AGFA (0.5 ml, 3.0 mg) in 0.01 M phosphatebuffered saline (PBS), pH 7.2, was continuously stirred in a test tube. To this mixture, 100 ¢1 glutaraldehyde (0.25% solution in water) was added dropwise over 5 min. The reaction was allowed to proceed for a further 10 min, and then 50 ~1 1 M L-lysine was added to stop the reaction. Free and bound daunomycin were separated by gel filtration through a Sepharose 6B column (25 x 1.5 cm) equilibrated with PBS. The fractions containing daunomycin-AGFA conjugates (D-AGFA) were dialyzed at 4 ° C for 24 h against two changes of PBS. After concentrating the D-AGFA conjugates to a desired volume (usually 5.0 ml) with negative pressure dialysis, the preparations were centrifuged once at 15,000 rpm for 1 h and stored at 4 ° C.
The average number of daunomycin molecules conjugated with one molecule of antibody was calculated from spectrophotometric measurements at 495 nm [E 1%/1 cm for daunomycin = 196 (Bernard et al., 1969) ] and protein concentrations were determined according to Lowry's method (Lowry et al., 1951) .
Pharmacologic Activity of D-AGFA
The pharmacologic activity of D-AGFA was measured in vitro by its inhibition of 3H-uridine incorporation into cellular RNA of tumor cells and by its direct cytotoxic action on MC-D cells as revealed by dye exclusion (0.2% trypan blue).
The assay for the inhibition of tumor ceil RNA synthesis was performed in microtiter plates with V-bottom wells (Cooke Engineering Co., Alexandria, Va.). The MC-D tumor cells were freshly prepared by digestion of tumor tissue with trypsin. The tumor cells were resuspended to contain 2 x 107 cells/ml in Dulbecco's modified Eagle's medium (DMEM: Grand Island Biological Co., New York, N.Y.) and 50 ~1 of this cell suspension (i.e., 106 cells) was dispensed into each well Daunomycin, either free or conjugated with AGFA, was adjusted to contain 5 vg/ml in DMEM and added to the wells in 50-~1 aliquots. The protein concentration of unconjugated AGFA was adjusted to the same level as that of D-AGFA. The plates were first incubated for 2 h at 37°C in a CO2 incubator; 1 ~Ci [5-3H] -uridine (New England Nuclear, Dorval, Quebec) in DMEM was then added to each well and the plates were incubated for another hour. The reaction was stopped by adding 25 ~xl 25% trichloroacetic acid (TCA) per well and the plates were kept at 4 ° C overnight. The TCA precipitates were washed twice with cold 5% TCA. They were solubilized in 0.1 ml 0.2 N NaOH and transferred to vials containing a toluene-based scintillation solution (PPO, 6 g; POPOP, 0.2 g in 1 1 of toluene) for counting of the incorporated 3H-uridine. All samples were assayed in triplicate.
Since it seemed possible that the inhibition of cellular RNA synthesis by D-AGFA might be due only to a temporary suppression of template activity without cell death, the trypan dye exclusion method, which directly evaluates the number of dead cells, was used to assess the toxic effect of D-AGFA on tumor cells. The experimental conditions, such as tumor cell number, D-AGFA concentration, and temperature of incubation, were identical with those in the previous experiment.
Antibody Activity of D-AGFA
The antibody activity of D-AGFA was demonstrated by the method of indirect immunofluorescence. Frozen MC-D tumor tissue was cut into sections approximately 4 ~m thick, which were thawed at room temperature and were then fixed with cold acetone on microscope slides. The fixed tissue sections were first treated with D-AGFA (1 mg/ml) for 45 min in a humid chamber, washed three times with cold PBS and then treated with FITC-conjugated rabbit anti-goat IgG antibodies (1 mg/ml) for 45 rain. Finally, the unreacted FITCconjugated antibodies were washed out and the sections were examined under a Zeiss fluorescence microscope. The control sections were treated with normal goat IgG instead of D-AGFA; the rest of the procedure was as described above.
In vivo Antitumor Effect of D-AGFA
In order to test the effect of D-AGFA on MC-D tumor in vivo, strain 13 guinea-pigs were inoculated subcutaneously on their flanks with a supralethal dose of MC-D tumor cells (106 per animal). On day 9, when the tumors had reached measurable sizes (0.5-0.9 cm diameter), the animals were divided into four groups, each of six tumor-bearing animals. One group of animals served as controls and did not receive any additional treatment. The other three groups received a total of seven intratumoral injections (0.5 ml/injection), given every other day, each injection for the respective groups consisting of (1) D-AGFA (2.5 ~g in terms of daunomycin concentration), (2) free daunomycin (2.5 ~xg), (3) unconjugated AGFA (0.5 rag); all these had been dissolved in PBS. The tumor growth was followed by measuring the two perpendicular diameters at 2 day intervals.
For the detection of tumor-specific immunity in animals in which the tumor had regressed, a second dose of 10 6 tumor cells was injected subcutaneously on the contralateral flank 35 days after the treatment had been stopped. Normal animals received the same number of tumor cells and were used as controls. the material became insoluble and could be removed by centrifugation. On the other hand, the second fraction, emerging in a volume similar to that of unconjugated A G F A (compare O.D. profiles A and B in Fig. 1 ), remained soluble under the same conditions. Therefore, only the second fraction was used in this study. The degree of coupling of daunomycin to A G F A by glutaraldehyde in the active D-AGFA fraction (i.e., the second fraction isolated by gel filtration) varied for different preparations, being in the range of 1 -2 molecules of daunomycin per molecule of antibody. The experimental conditions described here for the production of active D -A G F A were found to be optimal, since varying any one of the reaction parameters, e.g., increasing glutaraldehyde concentration, prolonging the reaction time, etc., produced a larger fraction of D-AGFA aggregates.
Results
Conjugation of Daunomycin with A GFA
D -A G F A was stable for 2 weeks when stored at 4 ° C; beyond this time daunomycin appeared to be gradually released from the conjugates.
Pharmacologic Activity of D-A GFA
Since an important biologic effect of daunomycin is the inhibition of the D N A template activity, the ability of D-A G F A to block the 3H-uridine incorporation into the RNA of MC-D tumor cells was used to measure its pharmacologic activity. The results listed in Table 1 clearly show that there was no significant difference in the inhibitory effects of D-AGFA and free daunomycin on 3H-uridine incorporation and it is therefore concluded that daunomycin in D-AGFA retained practi- (106) incorporation ( The results obtained in the trypan blue dye exclusion experiments, which are given in Table 2 , also indicate that D -A G F A possessed pharmacologic activity essentially identical with that of free daunomycin. As is shown in Table 2 , a substantial amount of tumor cells died after incubation for 2 h with free or bound daunomycin, the number of dead cells increasing slightly after incubation for an additional 2 h. These results also show that the toxic effect of daunomycin actually resulted in the death of tumor cells and did not only temporarily inhibit their D N A template activities. It is to be pointed out that clumping of tumor cells was observed in the samples treated with A G F A alone, which was unexpected since there is no obvious reason why A G F A would combine with MC-D tumor cells; this effect may have been due to the presence of fibrin fragments on the surface of freshly prepared tumor cells, which would provide a source of antigen for reaction with AGFA.
Antibody Activity of D-AGFA
The antibody activity of D-AGFA was demonstrated by indirect immunofluorescence. 
In vivo Antitumor Effects of D-AGFA
For the evaluation of the in vivo antitumor effects of D-AGFA, one group of six tumor-beating animals received seven intratumoral injections of D-AGFA on alternate days (a total of 17.5 p~g daunomycin was given). The tumors regressed completely in three of these animals. The tumor growth in the other three guinea-pigs was somewhat suppressed initially, but all these animals succumbed eventually to the tumors. Free daunomycin or unconjugated AGFA failed to affect the tumor growth in two other groups of guinea-pigs, which had received 106 tumor cells. All these findings are represented in Figure 3 . The three surviving guinea-pigs were rechallenged with the supralethal dose of 106 MC-D tumor cells 35 days after the treatment had beer~ stopped, but no tumor growth could be detected. On the other hand, normal guinea-pigs receiving the identical dose of tumor cells at the same time developed tumors as usual and eventually died 50-60 days after implantation of the MC-D cells.
Discussion
The use of drug-antibody conjugates as antitumor agents represents a practical approach for immunotherapy of tumors, provided that the drug-antibody conjugates retain both their antibody activity and the pharmacologic cytotoxicity of the bound drug, and that the conjugates are capable of selectively destroying tumor cells without affecting normal tissues. The results of this study, although not extensive because of the difficulty in obtaining a sufficient number of inbred guinea-pigs, support the conclusion that D-AGFA satisfies these criteria and that similar antibody conjugates may prove to be effective therapeutic agents for the destruction of other tumors that are lodged within a fibrin matrix or have fibrin attached to their membranes.
From the standpoint of cancer therapy, the most important demonstraion in this study is that D-AGFA could induce complete eradication of established MC-D tumors in strain 13 guinea-pigs. The tumors (with average diameter 0.7 cm when treatment was begun) in 50% of the animals had completely regressed after they had been injected with a total dose of 17.5 p~g daunomycin in the form of D-AGFA. These animals were free of any detectable tumor for over a year (as of the time of writing this paper). Tumor growth in the other 50% of the animals that received the same treatment was considerably retarded, although they eventually died of large tumors. On the other hand, the tumors in all other animals treated with free daunomycin of unconjugated AGFA, as well as in the untreated controls, grew progressively and all these animals died 50-60 days after tumor cell inoculation.
The antitumor activity of D-AGFA is attributed to the action of daunomycin, which has been repeatedly shown to be strongly toxic for tumor cells. The basic mechanism of the toxic effect of daunomycin has been ascribed to its ability to form complexes with DNA (Zunino et al., 1972; DiMarco, 1973) , thereby altering the stereochemical structure of the DNA molecule, which leads, in turn, to the inhibition of the enzymes involved in replication. It is therefore essential for the daunomytin to penetrate into the ceil nucleus in order to exert its cytotoxic effect.
The exact mechanism by which the covalently bound daunomycin residues exert their toxic effect on tumor cells is still not clear. However, at least three possibilities can be envisaged. The first is that D-AGFA, once on the surface of the cell membrane, releases dannomycin, which can penetrate the tumor cell and thus becomes available for interaction with nuclear DNA. However, the antitumor effect of D-AGFA cannot be simply explained by the dissociation of daunomycin from it, since the intratumoral injection of daunomycin alone did not produce the same effect. Failure of the latter treatment to suppress tumor growth could be attributed to the rapid plasma clearance of daunomycin (DiFronzo et al., 1971; Yesair et al., 1972) from the tumor site, resulting in an insufficient amount of the drug remaining at the site for effective killing of the tumor cells. If this explanation is plausible, one may suggest that the cytotoxic effectiveness of D-AGFA vis-~t-vis tumor cells is due to the fact that the clearance rate of the conjugate, particularly after binding to the fibrin matrix within the tumor mass, is much slower than that of the free drug. Thus, AGFA would function as a 'concentrating agent' for daunomycin within the tumor site.
Another possible mechanism is that D-AGFA conjugates enter the tumor cells by pinocytosis and that active daunomycin molecules are released gradually after intracellular digestion of the conjugates by enzymes.
The third possibility is that tumor regression was caused by tumor-specific immunity, which was induced as a result of the drug action on tumor cells. This interpretation is supported by the fact that after rejection of a lethal dose of MC-D cells induced by D-AGFA, the surviving animals could reject the second tumor cell inoculum a long time after the expected clearance of D-AGFA. However, it is not possible on the basis of these limited data to state whether or not tumor immunity had been induced within the first few days after the intratumoral inoculation of D-AGFA, and whether it contributed to the rejection of the first tumor graft. In relation to these findings, it is to be pointed out that several investigators have reported that tumor-specific immunity can be detected in the hosts surviving chemotherapy (Potter and Waiters, 1973; Bast et al., 1976) . How-ever, whereas injection of unconjugated A G F A did not affect the tumor growth, it is interesting to note that the intratumoral administration of antibodies to the fibrin fragment E resulted in complete regression of a line-10 hepatoma growing intradermally in strain 2 guinea-pigs (Schlager and Dray, 1975) .
In conclusion, the results of this study demonstrate that it is possible to induce tumor destruction with drugs conjugated to antibodies, which are directed against antigenic determinants present in the vicinity of tumor cells rather than against tumor antigens themselves. In the present system, advantage was taken of the fact that the MC-D tumor was growing within a fibrin lattice and of the opportunity of to producing specific antifibrin antibodies in large amounts. Moreover, the previous observation ) that 70% of the intravenously injected A G F A (as distinct from the intratumoral route used in this study) was localized in the tumor site indicates that A G F A had a strong affinity for the fibrinspecific antigens and that consequently most, if not all, of the cytotoxicity associated with D -A G F A was present in the tumor foci rather than distributed in other organs. By contrast, the preparation of tumor-specific antibodies in adequate amounts for the preparation of the corresponding cytotoxic conjugates is fraught with enormous difficulties and this is, at least in part, the reason for the lack of success reported in other studies on using this approach for eradication of tumors.
In view of the fact that fibrin has been conclusively demonstrated to be associated with many tumors (Lee et al., 1978; O'Meara, 1958; D a y et al., 1959) , including early metastatic tumor cells (Chew and Wallace, 1976) , and since we had previously shown that A G F A can localize in the fibrin matrix of tumor foci after i.v. injection (Lee et al., 1978) , we believe that the i.v. injection of conjugates consisting of cytotoxic drugs with purified antifibrin antibodies may provide an effective therapeutic procedure for the total eradication of the tumor cells remaining after surgical removal of the bulk of the tumor or after massive chemotherapy and radiation treatment, and thus prevent metastasis of recurrence of the tumor. Obviously, in order to confirm these conclusions, further studies are required with larger numbers of inbred guinea-pigs and with other tumor systems growing within a fibrin matrix or in association with fibrin.
